Viral vector CDMO Vibalogics latest private equity target

eggs being use to develop virus
Vibalogics in Cuxhaven, Germany, has become the latest target of private equity as investors seize the opportunities for CDMOs with expertise in gene and cell therapies. (Vibalogics)

With the market for new oncolytic viral and gene therapies developing rapidly, it is no surprise that private equity investors are looking for small contract manufacturers they can buy, build and sell off.  Ampersand Capital Partners is one of the players in the middle of that scramble.  

Just weeks after selling its share in Brammer Bio in a $1.7 billion deal, Ampersand has an agreement to buy Germany-based Vibalogics. The 50-person CDMO with a specialization in viruses has a 27,000-square-foot facility in Cuxhaven, Germany. Terms of the deal were not disclosed.

“Given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company,” David Anderson, Ampersand general partner, said in a statement.

RELATED: Catalent pulls off $1.2B deal for gene therapy CDMO Paragon Bioservices


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

Vibalogics CEO Stefan Beyer said the company will be able to tap Ampersand’s investment to grow its process development and manufacturing capabilities and expand in the U.S. and Europe.

The deal comes as large CDMOs have snapped up smaller ones with expertise in gene and cell therapies so they have an offering as biotechs look for contractors to help them develop them. In March, Ampersand Capital Partners sold Brammer Bio for $1.7 billion to Thermo Fisher Scientific, which has been building out its contract manufacturing operations since buying Patheon in 2017. The Cambridge, Massachusetts-based Brammer has expertise in viral vector manufacturing.

In April, Catalent agreed to ante up $1.2 billion for Paragon, a contractor with expertise in adeno-associated virus vectors, plasmids and lentivirus vectors. Owners of the Baltimore-based company included private equity investors NewSpring Health Capital and Camden Partners.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.